Paris, France, April 9, 2025 – Coave Therapeutics (‘Coave’), a company pioneering the future of genetic medicines, announces that members of its leadership team will be attending the following industry conferences:
Cell & Gene Meeting on the Med – April 15-17
Rome, Italy
CEO Rodolphe Clerval will be participating in a panel discussion – Science slam: Ocular Indications – on April 15 at 13:45 CEST
Rodolphe Clerval will also give a Company Presentation on April 15 at 15:00 CEST
ARVO (Association for Research in Vision and Ophthalmology) – May 4-8
Salt Lake City, UT, USA
BioEquity Europe – May 12-14
Bruges, Belgium
ASGCT (American Society of Gene and Cell Therapy) – May 13-17
New Orleans, LA, USA
***
About Coave Therapeutics
Coave Therapeutics is a genetic medicine company pioneering the development of innovative solutions to enhance the precision, safety, efficacy and manufacturability of genetic medicines. With its proprietary ALIGATER™ platform, Coave is at the forefront of addressing challenges in gene therapy delivery to extra-hepatic tissues, creating a robust pipeline targeting CNS, neuromuscular and eye diseases.
Headquartered in Paris, France, Coave Therapeutics is backed by leading international life sciences investors. For more information about the science, pipeline, and people, please visit coavetx.com and follow us on LinkedIn.
CONTACTS
Coave Therapeutics
Rodolphe Clerval, CEO
contact@coavetx.com
MEDiSTRAVA
Sylvie Berrebi, Mark Swallow
coavetx@medistrava.com
